Joseph C. Galante - 01 Dec 2022 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Joseph C. Galante by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
01 Dec 2022
Net transactions value
+$3,446
Form type
4
Filing time
23 Dec 2022, 16:10:18 UTC
Previous filing
23 Dec 2022
Next filing
23 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Purchase $151 +65 +0.12% $2.33 55,871 01 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $150 +65 +0.12% $2.31 55,936 02 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $142 +65 +0.12% $2.19 56,001 05 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $142 +65 +0.12% $2.19 56,066 06 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $142 +65 +0.12% $2.18 56,131 07 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $142 +65 +0.12% $2.19 56,196 08 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $140 +65 +0.12% $2.15 56,261 09 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $139 +65 +0.12% $2.14 56,326 12 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $262 +120 +0.21% $2.18 56,446 13 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $265 +120 +0.21% $2.21 56,566 14 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $134 +60 +0.11% $2.24 56,626 15 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $222 +100 +0.18% $2.22 56,726 16 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $552 +250 +0.44% $2.21 56,976 19 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $462 +200 +0.35% $2.31 57,176 20 Dec 2022 Direct F1
transaction CPIX Common Stock Purchase $400 +180 +0.31% $2.22 57,356 21 Dec 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.